2-Fluoromethamphetamine (2-FMA)
2-FMA is a ring-fluorinated analogue of methamphetamine marketed as a functional research-chemical stimulant valued anecdotally for clean, focus-oriented effects with less euphoria. Despite popularity in nootropic circles, it has essentially no human safety data and carries the cardiovascular and dependence risks of substituted amphetamines.
01 Overview
2-Fluoromethamphetamine places a fluorine at the 2-position of the methamphetamine aromatic ring. It appeared on research-chemical markets in the 2010s and is often described by users as a smoother, more controllable stimulant used for productivity.
No clinical trials or pharmacokinetic studies exist; knowledge is limited to anecdote and analytical identification. As a substituted amphetamine it should be presumed to carry meaningful abuse, cardiovascular and neurotoxic risk.
02 Mechanism
Acts as a releasing agent / reuptake inhibitor of norepinephrine and dopamine, analogous to methamphetamine with the fluorine modifying potency and metabolism.
03 Dosing
| Tier | Dose | Route | Notes |
|---|---|---|---|
| Light (approximate, anecdotal) | 10–25 mg | Insufflated | Harsher, shorter; discouraged. |
| Common (approximate, anecdotal) | 15–40 mg | Oral | User-reported functional range; no validated data. |
04 Effects
| Effect | Magnitude | Evidence | |
|---|---|---|---|
| Focus and wakefulnessUsers report clean stimulation and improved concentration with modest euphoria. | Moderate | Anecdotal | |
| Appetite suppressionTypical sympathomimetic appetite reduction. | Moderate | Anecdotal |
05 Side effects
| Effect | Severity | Frequency | Evidence | Countermeasures |
|---|---|---|---|---|
| Cardiovascular stimulationIncreased heart rate and blood pressure. | Moderate | Common | Anecdotal | |
| Insomnia and comedown dysphoriaDifficulty sleeping and low mood after effects wear off. | Moderate | Common | Anecdotal |